Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

SYDNEY, Australia, April 26, 2007 /PRNewswire-FirstCall/ -- Australian drug development company Alchemia Limited today announced preliminary results from its randomised Phase II clinical trial in patients with metastatic colorectal cancer, where Alchemia's drug HyCAMP(TM) was compared to irinotecan which is considered to be a cornerstone drug for the treatment of colorectal cancer. This announcement is being made at a preliminary stage of the analysis in accordance with the ASX disclosure requirements once the company became aware of the results reported below.

Primary safety endpoint - Comparison of the incidence of late grade 3 or 4 diarrhoea in patients receiving HyCAMP(TM) versus irinotecan alone:

    -- not met due to lower than expected incidence of diarrhoea in the

       control arm


    Secondary safety endpoints:


    -- No major differences in overall adverse events between the two

       treatment arms


    Secondary efficacy endpoints:


    -- 38 of 41 (93%) HyCAMP(TM) patients compared to 28 of 35 (80%)

       irinotecan patients completed 2 cycles (p=0.099)


    -- 14 of 41 (34%) HyCAMP(TM) patients compared to 5 of 35 (14%) irinotecan

       patients completed the full 8 cycles (p=0.064)


    -- Patients on HyCAMP(TM) received a median of 6 cycles of therapy,

       compared to 2 for irinotecan alone (p=0.005)


    -- Median progression free survival for HyCAMP(TM) patients was 5.2

       months, compared to 2.4 months for the irinotecan arm (p=0.014).

The Phase II trial commenced in December 2004 and patient accrual closed on 30 June 2006. In the randomised trial, 80 patients with metastatic colorectal cancer who had previously failed treatment with the anti-cancer drug 5-fluoro uracil were eligible to receive up to eight cycles of chemotherapy in the form of irinotecan or HyCAMP(TM) intravenously. The primary endpoint of the trial was safety (incidence
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc ... the Company has received a complete response letter ... for its New Drug Application (NDA) for the ... the treatment of hypertension.   Photo - ... are disappointed in the receipt of a complete ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Oct. 27 According to Millennium Research Group ... intelligence, the European arthroscope market generated over $30 ... over 2009 due to decreasing scope prices and ... Due to unfavorable economic conditions, manufacturers are ...
... today announced that it has received approval from the ... (US 7,815,929) regarding a method for the preparation, storage ... very nature, the process of compounding suppositories is cumbersome, ... Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. ...
Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Eating red meat or processed meat can increase your ... in the Journal of the National Cancer Institute. ... is why often colon cancer is also called colorectal ... growth of abnormal or malignant cells within the lining ...
... impotence latest research shows that Viagra //(sildenafil) may also ... and breathe easier. Children diagnosed with pulmonary arterial hypertension ... extremely high in the arteries that supply the lungs, ... and if left untreated, could eventually lead to death ...
... the study published in the Archives of Internal Medicine high ... of premenstrual syndrome (PMS). Previous studies have shown that blood ... PMS.PMS that occurs monthly during the reproductive age of ... a number of symptoms in a significant number of women ...
... family bonds, its friendship that can keep people have a ... that the benefits of having friends do affect the health ... life expectancy can get significantly increased. ,The researchers ... person or over the phone for about ten years in ...
... second phase of study that is trying new approaches ... of the drug topotecancan be more effective in children ... Children's Research Hospital, US, feel that the cancer drug ... patient of neuroblastoma as not all doses are effective ...
... to 6 years of age will eat as much as they ... behavior suggests that preschool children eat as much as they are ... was accepted that these children ate depending on how much they ... last meals were. New research had just negated all these factors ...
Cached Medicine News:
... D-Stat Flowable Hemostat has a ... topical application, such as vascular access ... It is also used as an ... of tissue tracts of femoral access ...
... Hemostasis Pad is intended for use in the ... sites and percutaneous catheters or tubes. The Pad ... powerful hemostatic agent. Chitosan gel is twice as ... which it is derived. When placed over the ...
... The EVS is engineered to close ... The ergonomic stapler with a simple ... operator. A deliver sheath gently ... maintains control of the site before, ...
The Prostar XL 8 is a suture mediated closure system. It can be used with 8F sheath. It has two 3-0 braided polyester sutures and also has the safety of guidewire....
Medicine Products: